U.S. FDA Approves IMBRUVICA® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease ...Middle East

IMBRUVICA® is now the only BTKi with 12 FDA approvals across seven indications, including five hematologic cancers and cGVHD HORSHAM, Pa., Aug. 24, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration...

Hence then, the article about u s fda approves imbruvica ibrutinib as first and only btki treatment for pediatric patients with chronic graft versus host disease was published today ( Thursday 25/08/2022 - 02:56 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( U.S. FDA Approves IMBRUVICA® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease )

Also on site :

• Kenya confirms first Ebola case after patient dies
• This Startup Led by an Ex-Apple Designer Thinks a GUI for AI Could Change Everything
• Experience ‘Harry Potter and the Half-Blood Prince’ in Stunning New Art; Illustrator Levi Pinfold Details the Process